再生障礙性貧血患兒血清中IL-17、IL-22表達及意義
發(fā)布時間:2019-02-15 21:29
【摘要】:目的本研究通過檢測兒童再生障礙性貧血(aplastic anemia,AA)血清中白細胞介素17(interleukin-17,IL-17)、白細胞介素22(interleukin 22,IL-22)的表達,并比較免疫抑制治療緩解及未緩解患兒治療前IL-17、IL-22的平均水平,初步探討兩者在兒童再生障礙性貧血中的作用。方法1.收集2015年12月至2016年12月鄭州大學第一附屬醫(yī)院兒科門診及病房初診60例再障患兒,分為重型再障(severe aplastic anemia,SAA)組和非重型再障(non-severe aplastic anemia,NSAA)組,SAA組20例,NSAA組40例。收集同期鄭州大學第一附屬醫(yī)院體檢的正常健康兒童25例為正常對照組。2.SAA組、NSAA組于確診后治療前抽取清晨空腹靜脈血2ml,正常對照組抽取清晨空腹靜脈血2ml,離心后獲得血清儲存于-80℃冰箱。3.ELISA方法檢測SAA組、NSAA組、正常對照組血清中細胞因子IL-17、IL-22的表達。4.分析SAA組、NSAA組、正常對照組各組中IL-17與IL-22的相關性。5.隨訪行免疫抑制治療(immunosuppressive therapy,IST)的患兒及免疫抑制治療6個月時的療效。6.所有數(shù)據(jù)均采用SPSS 21.0軟件處理,各組間年齡比較采用Kruskal-Wallis秩和檢驗,各組間性別比較采用獨立的多組二分類資料的卡方檢驗。計量資料采用均數(shù)±標準差(sx±)或中位數(shù)、四分位數(shù)表示。兩獨立樣本均數(shù)比較采用t檢驗。多個樣本均數(shù)比較采用單因素方差分析,兩兩比較采用LSD-t檢驗。兩連續(xù)變量間相關性采用Perason相關分析,以α=0.05為檢驗水準。結果1.SAA組、NSAA組及正常對照組三組間年齡、性別無明顯差異,差異無統(tǒng)計學意義(P0.05)。2.SAA組血清IL-17水平為(225.65±31.87)pg/ml,NSAA組為(198.37±42.66)pg/ml,均顯著高于正常對照組(79.37±51.70)pg/ml,差異有統(tǒng)計學意義(P0.05)。SAA組IL-17水平高于NSAA組,兩組比較差異有統(tǒng)計學意義(P0.05)。3.SAA組血清IL-22水平為(51.09±10.39)pg/ml,NSAA組為(38.99±10.25)pg/ml,均顯著高于正常對照組(15.20±5.98)pg/ml,其差異有統(tǒng)計學意義(P0.05)。SAA組IL-22水平高于SAA組,兩組比較差異有統(tǒng)計學意義(P0.05)。4.SAA組及NSAA組血清IL-17水平與IL-22水平均呈直線正相關(r=0.489,P=0.029,r=0.336,P=0.034),正常對照組血清IL-17水平與IL-22水平無明顯相關性(r=0.169,P=0.42)。5.60例初診再障患兒,50例行免疫抑制治療(抗胸腺細胞球蛋白和/或環(huán)孢素A),隨訪至2017年3月,8例(2例SAA,6例NSAA)隨訪時間6個月。6個月評價療效,24例部分/完全緩解,18例免疫抑制治療后未緩解。行IST緩解患兒治療前血清IL-17、IL-22平均水平均低于未緩解患兒(197.33±46.67pg/ml vs 219.55±29.15pg/ml,41.23±10.17pg/ml vs 44.74±10.95pg/ml),但差異無統(tǒng)計學意義(P0.05)。結論1.IL-17、IL-22在初診再障中的表達升高,且SAA組IL-17、IL-22水平高于NSAA組,提示IL-17、IL-22可能參與兒童再障的發(fā)病,并可作為再障嚴重程度的評判指標。2.再障患兒IL-22的表達與IL-17呈正相關。3.再障患兒免疫抑制治療有效,IL-17、IL-22的水平可能與治療效果無關聯(lián)。
[Abstract]:Objective to investigate the expression of interleukin 17 (interleukin-17,IL-17) and interleukin 22 (interleukin 22 IL-22) in the serum of children with aplastic anemia (aplastic anemia,AA). The average level of IL-17,IL-22 in children with remission and non-remission before treatment was compared, and the role of IL-17,IL-22 in children with aplastic anemia was discussed. Method 1. From December 2015 to December 2016, 60 newly diagnosed children with aplastic anemia in pediatric outpatient and ward of the first affiliated Hospital of Zhengzhou University were divided into severe aplastic anemia (severe aplastic anemia,SAA) group and non-severe aplastic anemia (non-severe aplastic anemia,NSAA) group, SAA group (20 cases). 40 cases in NSAA group. During the same period, 25 healthy children in the first affiliated Hospital of Zhengzhou University were collected as normal control group. In 2.SAA group, 2 ml of early morning fasting venous blood was taken from NSAA group and 2 ml of fasting venous blood was collected from normal control group before treatment. After centrifugation, the serum was stored in -80 鈩,
本文編號:2423712
[Abstract]:Objective to investigate the expression of interleukin 17 (interleukin-17,IL-17) and interleukin 22 (interleukin 22 IL-22) in the serum of children with aplastic anemia (aplastic anemia,AA). The average level of IL-17,IL-22 in children with remission and non-remission before treatment was compared, and the role of IL-17,IL-22 in children with aplastic anemia was discussed. Method 1. From December 2015 to December 2016, 60 newly diagnosed children with aplastic anemia in pediatric outpatient and ward of the first affiliated Hospital of Zhengzhou University were divided into severe aplastic anemia (severe aplastic anemia,SAA) group and non-severe aplastic anemia (non-severe aplastic anemia,NSAA) group, SAA group (20 cases). 40 cases in NSAA group. During the same period, 25 healthy children in the first affiliated Hospital of Zhengzhou University were collected as normal control group. In 2.SAA group, 2 ml of early morning fasting venous blood was taken from NSAA group and 2 ml of fasting venous blood was collected from normal control group before treatment. After centrifugation, the serum was stored in -80 鈩,
本文編號:2423712
本文鏈接:http://sikaile.net/yixuelunwen/eklw/2423712.html
最近更新
教材專著